0.53% Less Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ) Shorted Shares

May 16, 2018 - By Billy Entrekin

Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ) had a decrease of its shorted shares by 0.53%. FINRA announced in May ARLZ’s total 3.37 million shorted shares. Previously was reported down change of 0.53% from 3.38M shares. With Average volume 355,900, ARLZ’s former position will take 10 days to restore. Aralez Pharmaceuticals Inchares float short is 6.49%.

ARLZ reached $0.47 during the last trading session after $0.01 change.Aralez Pharmaceuticals Inc. has volume of 1.01M shares. Since May 16, 2017 ARLZ has declined 41.74% and is downtrending. The stock underperformed the S&P 500 by 53.29%.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada.The firm is valued at $30.56 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas.Last it reported negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

There’s a significant Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) news published by Seekingalpha.com. It’s a report titled: “Aralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining” on May 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: